Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma

Frontiers in Endocrinology
Mariah L Farrell, Michaela R Reagan

Abstract

It is becoming clear that myeloma cell-induced disruption of the highly organized bone marrow components (both cellular and extracellular) results in destruction of the marrow and support for multiple myeloma (MM) cell proliferation, survival, migration, and drug resistance. Since the first phase I clinical trial on bortezomib was published 15 years ago, proteasome inhibitors (PIs) have become increasingly common for treatment of MM and are currently an essential part of any anti-myeloma combination therapy. PIs, either the first generation (bortezomib), second generation (carfilzomib) or oral agent (ixazomib), all take advantage of the heavy reliance of myeloma cells on the 26S proteasome for their degradation of excessive or misfolded proteins. Inhibiting the proteasome can create a crisis specifically for myeloma cells due to their rapid production of immunoglobulins. PIs have relatively few side effects and can be very effective, especially in combination therapy. If PI resistance can be overcome, these drugs may prove even more useful to a greater range of patients. Both soluble and insoluble (contact mediated) signals drive PI-resistance via activation of various intracellular signaling pathways. This review discusses the...Continue Reading

References

Jan 17, 2003·Mayo Clinic Proceedings·Robert A KylePhilip R Greipp
May 4, 2004·Nature Reviews. Cancer·Julian Adams
Mar 21, 2006·Immunity·Kalle-Pekka NeraOlli Lassila
Jul 19, 2006·British Journal of Haematology·Reshma ShringarpureKenneth C Anderson
Nov 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter M VoorheesRobert Z Orlowski
May 4, 2010·Molecular Cancer·Seong-Su HanSiegfried Janz
Dec 22, 2010·Proceedings of the National Academy of Sciences of the United States of America·Bernhard KlooDaniel Krappmann
Aug 19, 2011·Molecular & Cellular Proteomics : MCP·Yun XiangJohn M Koomen
Nov 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michaela R Reagan, Irene M Ghobrial
Jan 5, 2012·PloS One·Erika SuzukiChristopher J Kirk
Feb 22, 2012·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Wenzhong QueDanrong Jiang
Mar 28, 2012·Biochemical and Biophysical Research Communications·Jing-li GuChang Su
Nov 1, 2012·Biochemical and Biophysical Research Communications·Dehui XuEls Van Valckenborgh
Mar 5, 2013·The Journal of Clinical Investigation·Aldo M RoccaroIrene M Ghobrial
Jul 2, 2014·Proceedings of the National Academy of Sciences of the United States of America·Archana SwamiIrene M Ghobrial
Dec 6, 2014·Blood Cancer Journal·B MuzA K Azab
Mar 21, 2015·Biochemical and Biophysical Research Communications·Shannon SanacoraIvana Vancurova
Dec 23, 2015·Pathology Oncology Research : POR·Xianjuan ShenShaoqing Ju
Mar 24, 2016·Annals of the New York Academy of Sciences·Heather FairfieldMichaela R Reagan
Jun 28, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yaodong ShenHong Liu

❮ Previous
Next ❯

Citations

Nov 9, 2018·International Journal of Molecular Sciences·Chia-Hung Yen, Hui-Hua Hsiao
Jan 24, 2019·Frontiers in Endocrinology·Danielle HarmerMichaela R Reagan
Sep 8, 2019·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Teodora Alexa-StratulatChiara Riganti

❮ Previous
Next ❯

Software Mentioned

BOSTON

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.